Individualized fracture risk assessment
- 1 July 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 25 (4), 532-541
- https://doi.org/10.1097/bor.0b013e328361ff8c
Abstract
Fragility fracture is a major public health burden, because it is associated with a substantial morbidity and mortality. Risk prediction models, including the Fracture Risk Assessment Tool (FRAX) and Garvan Fracture Risk Calculator (GFRC), have been developed to provide a useful clinical framework for communicating the risk of fracture. The present review examines the validation of risk prediction models in osteoporosis and identifies some major challenges. Recent validation studies suggested that the area under the ROC curve in fracture discrimination ranged from 0.61 to 0.83 for FRAX, and from 0.63 to 0.88 for GFRC, with hip fracture having a better discrimination than fragility fractures as a group. FRAX substantially underestimated the risk of fracture, whereas the predicted risk by GFRC was close to or slightly higher than the actual risk. Results of post-hoc analyses of clinical trials indicated the antifracture efficacy of alendronate, coronate, bazedoxifene, and denosumab was greater in patients with higher predicted risk of fracture. However, there was no correlation between antifracture efficacy and predicted fracture risk among patients on raloxifene and strontium ranelate. The prognostic performance of FRAX and GFRC for fracture prediction is not perfect, but these predictive models can aid patients and doctors to communicate about fracture risk in the medium term and to make rational decisions. However, the application of these predictive models in making decisions for an individual should take into account the individual's perception of the importance of the risk of fracture and its severity outcomes.Keywords
This publication has 64 references indexed in Scilit:
- Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and MenJournal of Clinical Endocrinology & Metabolism, 2011
- Effect of Osteoporosis Treatment on Mortality: A Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2010
- Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and WomenJAMA, 2009
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureThe New England Journal of Medicine, 2007
- Residual Lifetime Risk of Fractures in Women and MenJournal of Bone and Mineral Research, 2007
- Risk of Subsequent Fracture After Low-Trauma Fracture in Men and WomenJAMA, 2007
- Mortality After Low-Energy Fractures in Patients Aged at Least 45 Years OldJournal of Orthopaedic Trauma, 2005
- Fracture risk following an osteoporotic fractureOsteoporosis International, 2003
- Age- and Gender-Specific Rate of Fractures in Australia: A Population-Based StudyOsteoporosis International, 1999
- Mortality after all major types of osteoporotic fracture in men and women: an observational studyThe Lancet, 1999